<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SEQUENT</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SEQUENT</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="sequent-scientific-limited" class="section level1">
<h1>Sequent Scientific Limited</h1>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SEQUENT.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="sequent-scientific-limited-investor-analysis-summary-as-of-november-2025" class="section level9">
<p class="heading"><strong>SeQuent Scientific Limited ‚Äì Investor Analysis Summary (as of November 2025)</strong></p>
<p><strong>Stock Code:</strong> SEQUENT (NSE) | 512529 (BSE)<br />
<strong>Industry:</strong> Life Sciences ‚Äì Animal Health &amp; Human Health APIs/Formulations<br />
<strong>Key Events:</strong> Merger with Viyash Life Sciences approved by NCLT on November 18, 2025</p>
<hr />
</div>
<div id="summary-of-performance-q2-fy-26-h1-fy-26" class="section level6">
<h6>‚úÖ <strong>Summary of Performance (Q2 FY ‚Äô26 / H1 FY ‚Äô26)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26</th>
<th>YoY Growth</th>
<th>H1 FY26</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Total Revenue</strong></td>
<td>‚Çπ4,240 Cr</td>
<td>+15%</td>
<td>‚Çπ8,654 Cr</td>
<td>+14%</td>
</tr>
<tr class="even">
<td><strong>Formulations Revenue (75% of sales)</strong></td>
<td>‚Çπ3,351 Cr</td>
<td>+18%</td>
<td>‚Çπ6,734 Cr</td>
<td>+15%</td>
</tr>
<tr class="odd">
<td><strong>API Revenue</strong></td>
<td>‚Çπ830 Cr</td>
<td>+7%</td>
<td>‚Çπ1,884 Cr</td>
<td>+11%</td>
</tr>
<tr class="even">
<td><strong>Gross Margin</strong></td>
<td>49.7%</td>
<td>+270 bps</td>
<td>48.3%</td>
<td>+230 bps</td>
</tr>
<tr class="odd">
<td><strong>EBITDA (Pre-ESOP)</strong></td>
<td>‚Çπ657 Cr</td>
<td>+47%</td>
<td>‚Çπ1,259 Cr</td>
<td>+35.4%</td>
</tr>
<tr class="even">
<td><strong>EBITDA Margin</strong></td>
<td>15.5%</td>
<td>+330 bps</td>
<td>14.5%</td>
<td>+220 bps</td>
</tr>
<tr class="odd">
<td><strong>PAT</strong></td>
<td>‚Çπ196 Cr</td>
<td>~3x</td>
<td>‚Çπ372 Cr</td>
<td>&gt;2x</td>
</tr>
<tr class="even">
<td><strong>PAT Margin</strong></td>
<td>~4.6%</td>
<td>‚Äî</td>
<td>~4.3%</td>
<td>Improved from 2%</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>Revenue mix:</strong> Formulations dominate (~75%) with strong growth in <strong>Europe</strong> (+14% YoY), <strong>emerging markets</strong> (+27% YoY), and <strong>India</strong> (+6% YoY).</li>
<li><strong>API business stabilizing:</strong> Growth at 7% after restructuring; one new U.S. API commercialized and FDA audit completed for research lab.</li>
<li><strong>ESOP expense:</strong> ~‚Çπ23 Cr in H1 FY26; expected to be ~‚Çπ34‚Äì35 Cr for full year, likely recurring over next 1‚Äì2 years.</li>
</ul>
<hr />
</div>
<div id="tailwinds-growth-catalysts" class="section level6">
<h6>üå¨Ô∏è <strong>Tailwinds (Growth Catalysts)</strong></h6>
<div id="merger-with-viyash-life-sciences-transformational-synergy" class="section level9">
<p class="heading">1. <strong>Merger with Viyash Life Sciences ‚Äì Transformational Synergy</strong></p>
<ul>
<li><strong>NCLT approval received</strong>, clearing the final legal hurdle; integration begins immediately.</li>
<li><strong>Combined quarterly revenue:</strong> ~‚Çπ852 Cr with <strong>16% YoY growth</strong> and <strong>EBITDA margin of 22%</strong>.</li>
<li><strong>Synergy drivers:</strong>
<ul>
<li><strong>R&amp;D:</strong> Combined innovation engine; 4 new companion animal products already developed; over <strong>70 new NCEs filed in past 3‚Äì4 years</strong> (40 APIs, 30 FDFs).</li>
<li><strong>Manufacturing:</strong> 8 FDA-approved sites under merged entity; SeQuent‚Äôs capacity constraints resolved via Viyash‚Äôs new production line.</li>
<li><strong>Vertical integration:</strong> SeQuent‚Äôs APIs moving in-house; Viyash backward/forward integrating key products ‚Üí <strong>margin expansion</strong>.</li>
<li><strong>Shared services &amp; procurement:</strong> Cost synergies from unified supply chain and corporate functions.</li>
</ul></li>
<li><strong>Balance sheet strength post-merger:</strong> Anticipated debt-free status by FY27; free cash flow to fund organic and inorganic growth.</li>
</ul>
</div>
<div id="companion-animal-pet-care-high-growth-strategic-focus" class="section level9">
<p class="heading">2. <strong>Companion Animal (Pet Care) ‚Äì High-Growth Strategic Focus</strong></p>
<ul>
<li><strong>Target segment:</strong> Therapeutics and supplements (not pet food).</li>
<li><strong>Synergy with human health expertise:</strong> Many pet health products mirror human formulations; Viyash‚Äôs R&amp;D backbone accelerates development.</li>
<li><strong>Market tailwinds:</strong>
<ul>
<li>Rising pet adoption globally.</li>
<li>Increased spending on pet wellness.</li>
<li>Slower genericization than human pharma ‚Üí higher pricing power.</li>
</ul></li>
<li><strong>India operations:</strong> Focus on building manufacturing capabilities (capex expected H2 FY27 or via inorganic route).</li>
</ul>
</div>
<div id="global-footprint-expansion-geographic-diversification" class="section level9">
<p class="heading">3. <strong>Global Footprint Expansion &amp; Geographic Diversification</strong></p>
<ul>
<li><strong>Europe:</strong> Strong recovery in Spain; Turkey exports growing; among top 5 ruminant players.</li>
<li><strong>Latin America:</strong> Tulaject (tulathromycin) launched in Brazil; Mexico front-end presence established.</li>
<li><strong>U.S.:</strong> Manufacturing base insulates against tariffs; CDMO and formulation growth engines.</li>
</ul>
</div>
<div id="operational-strategic-overhaul" class="section level9">
<p class="heading">4. <strong>Operational &amp; Strategic Overhaul</strong></p>
<ul>
<li><strong>Product portfolio optimization:</strong> Divested commoditized products (e.g., antiretrovirals); shifted to value-added generics.</li>
<li><strong>Network rationalization:</strong> 3 intermediate sites divested; consolidated operations to improve margins.</li>
<li><strong>Cost control:</strong> Gross margins rising consistently (47% ‚Üí 49.7% YoY) due to internalization and efficiency.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>Headwinds &amp; Risks</strong></h6>
<div id="merger-integration-risk" class="section level9">
<p class="heading">1. <strong>Merger Integration Risk</strong></p>
<ul>
<li>While synergies are identified and timeline set (12‚Äì18 months), <strong>execution risk remains</strong> in combining cultures, IT systems, and operational workflows.</li>
<li>Regulatory filings and client approvals may delay benefits (e.g., some innovator audits take up to 2 years).</li>
</ul>
</div>
<div id="market-demand-volatility" class="section level9">
<p class="heading">2. <strong>Market &amp; Demand Volatility</strong></p>
<ul>
<li><strong>Geopolitical factors:</strong> FX fluctuations, supply chain disruptions, and trade policies could affect international operations, particularly in emerging markets.</li>
<li><strong>Slow genericization in animal health:</strong> Unlike human generics, transitions from branded to generic are slower ‚Üí revenue recognition lag.</li>
</ul>
</div>
<div id="tariff-regulatory-risks-perceived-but-low-immediate-risk" class="section level9">
<p class="heading">3. <strong>Tariff &amp; Regulatory Risks (Perceived, but Low Immediate Risk)</strong></p>
<ul>
<li>Management downplays U.S. tariff impact due to local manufacturing.</li>
<li>However, any future U.S. trade policy changes (e.g., scrutiny on Indian APIs) could pose headwinds.</li>
<li>Regulatory compliance burden is increasing (especially in EU/US), but seen as a <strong>competitive moat</strong>, not a risk, for SeQuent.</li>
</ul>
</div>
<div id="rd-cycle-and-timing-of-benefits" class="section level9">
<p class="heading">4. <strong>R&amp;D Cycle and Timing of Benefits</strong></p>
<ul>
<li><strong>Near-term margin improvements</strong> are sustainable, but <strong>R&amp;D synergies are longer-term (2027‚Äì2029)</strong>.</li>
<li>Delays in product development or regulatory approvals could temper growth expectations.</li>
</ul>
</div>
<div id="esop-costs" class="section level9">
<p class="heading">5. <strong>ESOP Costs</strong></p>
<ul>
<li>Rising ESOP expenses (~‚Çπ34‚Äì35 Cr in FY26) will pressure margins.</li>
<li>While justified for talent retention post-merger, it‚Äôs <strong>not a one-off</strong> and may impact near-term net profitability.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-outlook" class="section level6">
<h6>üìà <strong>Growth Prospects &amp; Outlook</strong></h6>
<div id="short-term-fy26fy27" class="section level9">
<p class="heading">Short-Term (FY26‚ÄìFY27)</p>
<ul>
<li><strong>Double-digit revenue growth (14‚Äì16%)</strong> expected to continue.</li>
<li><strong>EBITDA margin trajectory:</strong> 15.5% ‚Üí <strong>targeting 20%+ by FY27</strong>, with sustained improvement.</li>
<li><strong>Free cash flow generation:</strong> Strong; expected to support deleveraging and capex.</li>
<li><strong>Combined entity reporting:</strong> From <strong>Q3 or Q4 FY26</strong>, providing clarity on synergy realization.</li>
</ul>
</div>
<div id="mid-to-long-term-20272030" class="section level9">
<p class="heading">Mid to Long-Term (2027‚Äì2030)</p>
<ul>
<li><strong>Strategic pivot to companion animals</strong> as a key differentiator.</li>
<li><strong>CDMO business ramp-up:</strong> 15+ high-value CDMO partnerships (&gt;$1B combined market value); revenue from 2028 onwards.</li>
<li><strong>Inorganic growth likely:</strong> Targeting front-end expansions in <strong>Europe</strong>, <strong>Latin America</strong>, and <strong>India-based manufacturing</strong> to fill gaps.</li>
<li><strong>Long-term vision:</strong> Build India‚Äôs <strong>first global animal health champion</strong> with integrated R&amp;D, API, FDF, and distribution.</li>
</ul>
<hr />
</div>
</div>
<div id="key-differentiators-moats" class="section level6">
<h6>üîë <strong>Key Differentiators (Moats)</strong></h6>
<ol style="list-style-type: decimal">
<li><strong>Vertically Integrated Model:</strong> From intermediates to finished formulations with robust internal supply chain.</li>
<li><strong>Regulatory Excellence:</strong> Multiple FDA-approved facilities ‚Äì rare in animal health sector.</li>
<li><strong>Science-first Approach:</strong> High R&amp;D focus with fast new product development across human and animal health.</li>
<li><strong>Complementary Strengths of Merger:</strong>
<ul>
<li><strong>SeQuent:</strong> Animal health distribution, global footprint.</li>
<li><strong>Viyash:</strong> Human health APIs, CDMO, U.S. footprint, strong balance sheet.</li>
</ul></li>
</ol>
<hr />
</div>
<div id="final-summary-key-takeaways" class="section level6">
<h6>üîö <strong>Final Summary: Key Takeaways</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Potential</strong></td>
<td>‚úÖ <strong>High</strong> ‚Äì Driven by generics, pet care, CDMO, and merger synergies. Double-digit growth sustainable.</td>
</tr>
<tr class="even">
<td><strong>Profitability Trend</strong></td>
<td>‚úÖ <strong>Improving</strong> ‚Äì Gross and EBITDA margins rising consistently; goal of 20%+ EBITDA by FY27 is credible.</td>
</tr>
<tr class="odd">
<td><strong>Balance Sheet</strong></td>
<td>‚úÖ <strong>Strengthening</strong> ‚Äì Deleveraging complete; post-merger entity is cash-rich, enabling strategic investments.</td>
</tr>
<tr class="even">
<td><strong>Execution Risk</strong></td>
<td>‚ö†Ô∏è <strong>Medium</strong> ‚Äì Merger integration and synergy realization are critical success factors.</td>
</tr>
<tr class="odd">
<td><strong>Valuation Catalyst</strong></td>
<td>üî• The market may re-rate SEQUENT post-merger as it transitions from an <strong>asset-heavy legacy player</strong> to a <strong>global, R&amp;D-driven life sciences leader</strong> with visibility into long-term growth engines.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="conclusion-buy-on-synergy-long-term-vision" class="section level6">
<h6>üìå Conclusion: <em>Buy on Synergy &amp; Long-Term Vision</em></h6>
<p><strong>SeQuent Scientific, post-merger with Viyash, is on track to become a differentiated, integrated life sciences player with exposure to high-growth segments in both human and animal health.</strong> The company‚Äôs focus on <strong>R&amp;D, operational excellence, low-cost manufacturing, and synergistic integration</strong> positions it for <strong>sustained double-digit growth and margin expansion</strong>.</p>
<blockquote>
<p>üéØ <strong>Ideal for investors seeking:</strong><br />
- A turnaround story completed<br />
- Exposure to global animal health innovation<br />
- Strong free cash flow and deleveraged balance sheet<br />
- Upside from merger synergies over 12‚Äì24 months</p>
</blockquote>
<p><strong>Monitor:</strong><br />
- Progress on synergy realization<br />
- FY27 margin trajectory (~20% target)<br />
- Inorganic announcements (M&amp;A appetite confirmed)<br />
- Quarterly EBITDA run-rate for the combined entity (&gt;‚Çπ200 Cr)</p>
<hr />
<p><strong>Date of Analysis:</strong> November 2025<br />
<em>Based on Q2 FY26 Earnings Call Transcript and Regulatory Filing</em></p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
